- $83.81bn
- $101.99bn
- £31.38bn
- 70
- 69
- 83
- 88
REG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Directorate Change
AnnouncementREG - GlaxoSmithKline PLC - Total Voting Rights
AnnouncementREG - GlaxoSmithKline PLC - Publication of 2021 AGM Notice
AnnouncementREG - GlaxoSmithKline PLC - GSK respiratory product sales reporting changes
AnnouncementREG - GlaxoSmithKline PLC - Moncef Slaoui Departs Galvani Bioelectronics
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Chair of Audit & Risk Committee
AnnouncementREG - GlaxoSmithKline PLC - Medicago and GSK start Phase 3 trial
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Annual Report 2020 on Form 20-F
Announcement